Jul 16, 2026 · 7 min
Netflix slips on weak guidance while Abbott and Eli Lilly surge
Netflix Drops, AtaiBeckley Jumps, Abbott Surges
Understanding these market movements reveals where corporate giants are placing their long-term bets, from streaming growth limits to emerging biotech frontiers.
- 1Netflix stock declined following weaker-than-expected third-quarter guidance that signaled slowing expansion.
- 2Eli Lilly acquired psychedelic drug developer Atai Life Sciences to bolster its mental health pipeline.
- 3Abbott Laboratories surged after upgrading its full-year profit outlook on strong demand.
Don't miss
Nora Melinda breaks down the implications of Eli Lilly acquiring Atai Life Sciences to enter the psychedelic drug space.
The brief
Tech and healthcare are driving the latest market shifts as Netflix faces growth headwinds while major pharmaceutical players make aggressive moves to expand their pipelines.
Netflix stock slipped after issuing weaker-than-expected third-quarter guidance, raising questions about whether the streaming giant can sustain its rapid expansion.
In healthcare, Eli Lilly is expanding into mental health treatments by acquiring psychedelic drug developer Atai Life Sciences, signaling rising corporate interest in alternative therapies.
Meanwhile, Abbott Laboratories surged after raising its full-year earnings forecast, proving that traditional medical device and diagnostics demand remains highly resilient.
What was said on this episode
13 statements · 7 positive · 2 negative · 4 neutral
Netflix is forecast to experience another quarter of slowing growth.
“Investors are digesting this forecast of another quarter of slowing growth.”
Listen at 1:06
Time spent watching Netflix grew about 2% in the first half of the year.
“time spent watching Netflix grew about 2% in the first half of the year”
Listen at 1:25
Netflix stock fell more than 40% over the past 12 months.
“Netflix is down about more than 40% over the past 12 months.”
Listen at 1:47
Eli Lilly is buying AtaiBeckley for nearly $4 billion.
“Eli Lilly buying a Ty Beckley. That's ticker at a I for just nearly $4 billion.”
Listen at 3:26
AtaiBeckley develops psychedelic drugs.
“This is a psychedelic drug developer.”
Listen at 3:33
AtaiBeckley's BLP003 is a nasal spray for treatment-resistant depression.
“This is a nasal spray for treatment resistance depression.”
Listen at 3:45
BLP003 is similar to Johnson & Johnson's Spravato, a psychedelic-adjacent drug.
“we do see this is kind of similar to JJ's bravado, which is essentially a psychedelic adjacent drug.”
Listen at 3:49
Eli Lilly and peers are expanding into psychedelic drugs.
“we're really seeing some of these big names like Eli Lilly and its peers branching out into a space that a lot of people once shied away from.”
Listen at 3:55
Eli Lilly rose 1% and AtaiBeckley rose 33%.
“Eli lilly was up 1% and of course, tie was up 33%.”
Listen at 4:03
Abbott Laboratories stock rose 11% that day.
“Abbott Labs finish things up with Abbott Laboratories. Ticker ABT stock up 11% on the day.”
Listen at 4:11
Abbott Laboratories was the S&P's best percentage performer that day.
“It was the best performer in the S and P by a percentage basis”
Listen at 4:17
Abbott Laboratories had its best trading day in more than six years.
“seeing its best day in more than six years.”
Listen at 4:29
Abbott Laboratories raised its 2026 profit outlook after a stronger-than-expected quarter.
“after it raises 20, 26 profit outlook following a stronger than expected quarter.”
Listen at 4:32
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Netflix
AtaiBeckley Inc.
psychedelicsBooks & mentions
Stock Movers
Stay updated on daily market-moving financial news and corporate earnings reports
Listen to the full episode and explore every guest, topic, and moment on PodLume.